The findings of a large US real-world cohort (n= 18,000) study, published in 2024, show that patients on tirzepatide were significantly more likely to achieve 5 %, 10 % and 15 % weight loss compared with semaglutide (HR 1.76, 2.54, 3.24, respectively), with a 12-month mean weight difference of -6.9% 8
All handling, storage, and experimental use should comply with standard laboratory safety protocols and institutional guidelines
Notably, a reduction in the potassium channel Kir4.1 and an increase in AQP4 in the astrocyte end-feet of ALS model rats indicate challenges in maintaining water and potassium balance, further compromising BBB stability [247]
Unadjusted p-value is derived from a two-sided Wilcoxon rank-sum test
Both are Novo Nordisk programs, but they employ fundamentally different molecular strategies
Excellent snapshot of the current incretin landscape